MedCity News
FEBRUARY 18, 2025
Highmark and Sword Health launched a new virtual pelvic health offering on Monday. The program connects members with a pelvic health specialist. The post Highmark Launches Virtual Pelvic Health Offering Powered by Sword Health appeared first on MedCity News.
PharmaVoice
FEBRUARY 18, 2025
Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 18, 2025
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues.
pharmaphorum
FEBRUARY 18, 2025
The FDA is scheduled to deliver a verdict on Sanofi and Regeneron's Dupixent for rare autoimmune skin disorder bullous pemphigoid in June
Advertiser: ZoomInfo
AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.
Pharmaceutical Technology
FEBRUARY 18, 2025
The FDA has accepted Gileads new drug application with a decision expected by 19 June 2025.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Commerce
FEBRUARY 18, 2025
In the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of sales, life sciences, Loftware, comments on why she believes supply chain collaboration is becoming increasingly critical today.
pharmaphorum
FEBRUARY 18, 2025
ALS candidates from Biohaven, Prilenia, Clene, and UCB were unable to slow disease progression in the study, but two showed signs of efficacy
PharmaTimes
FEBRUARY 18, 2025
New data has shown that around a third of women do not attend screenings after being invited
PharmaTech
FEBRUARY 18, 2025
Benjamin McLeod, Abhi Naravane, PhD, MBA, and Marianna Tcherpakov PhD go behind the headlines to talk about the latest big acquisitions, GLP-1 Super Bowl advertising, and changes in NIH funding.
Speaker: Jesse Hunter and Brynn Chadwick
Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.
Pharmaceutical Technology
FEBRUARY 18, 2025
Product sales for the vaccine specialist Valneva reached 170m despite slow US sales of its chikungunya vaccine.
pharmaphorum
FEBRUARY 18, 2025
Shionogi will market the EndeavorRide app, originally licensed from Akili, in Japan following its approval by the MHLW regulator
Pharmaceutical Technology
FEBRUARY 18, 2025
The US FDA has granted fast track designation to Rznomics' RZ-001 for the treatment of hepatocellular carcinoma (HCC).
PharmExec
FEBRUARY 18, 2025
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Advertiser: ZoomInfo
ZoomInfo customers aren’t just selling — they’re winning. Revenue teams using our Go-To-Market Intelligence platform grew pipeline by 32%, increased deal sizes by 40%, and booked 55% more meetings. Download this report to see what 11,000+ customers say about our Go-To-Market Intelligence platform and how it impacts their bottom line. The data speaks for itself!
Pharmaceutical Technology
FEBRUARY 18, 2025
HMRI has signed a memorandum of understanding (MoU) with Novartis Australia for expediting medical research to drive healthcare projects.
PharmExec
FEBRUARY 18, 2025
Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in multiple myeloma and solid tumor bone metastases.
Pharmaceutical Commerce
FEBRUARY 18, 2025
The latest news for pharma industry insiders.
PharmExec
FEBRUARY 18, 2025
In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro gives an update on the preclinical development of Abpro's lead HER2/CD3 T cell engager.
Speaker: Kevin Burke
AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.
Pharmaceutical Commerce
FEBRUARY 18, 2025
A qualitative study examines how Medicaid telehealth reimbursement policies affect staffing and patient-centered care.
PharmExec
FEBRUARY 18, 2025
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
PharmaTech
FEBRUARY 18, 2025
Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
PharmExec
FEBRUARY 18, 2025
John Arena, interim president of global pharma services at Cencora, discusses how companies can continue to develop launch strategies while taking potential regulatory changes into consideration.
Advertiser: ZoomInfo
Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.
Pharmacy Times
FEBRUARY 18, 2025
Research suggests H5N1 may be spreading undetected among humans, particularly in veterinarians with frequent animal exposure.
PharmExec
FEBRUARY 18, 2025
Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, close the trust gap, and so much more.
Pharmacy Times
FEBRUARY 18, 2025
New data from the longest known trial of pediatrics and adolescents in the postacute phase of COVID-19 show they are at a heightened risk of gastrointestinal tract symptoms.
MedCity News
FEBRUARY 18, 2025
If you rely on federal grants as your sole means of support, youre tying your destiny to forces outside your control. There are other roads to success in health and medical research. By pursuing them, you might gain more freedom, fewer administrative hurdles, and the chance to save lives faster. The post Will the Entire NIH be Shut Down? appeared first on MedCity News.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Pharmacy Times
FEBRUARY 18, 2025
Clinical decision support systems based on algorithms have improved outcomes and reduced costs in other health care settings.
MedCity News
FEBRUARY 18, 2025
Romvimza, a drug for treating tenosynovial giant cell tumor, was initially developed by Deciphera Pharmaceuticals. Last year, Ono Pharmaceutical acquired Deciphera to build up its oncology portfolio and expand its business prospects in the U.S. and Europe. The post Ono Pharma Drug Acquired in $2.4B Deal Wins FDA Approval for Treating Rare Type of Tumor appeared first on MedCity News.
Pharmacy Times
FEBRUARY 18, 2025
Although larsucosterol did not show statistical significance, it showed clinically meaningful trends in 90-day mortality in patients with severe alcohol-associated hepatitis.
Expert insights. Personalized for you.
244 
Let's personalize your content